Pasar al contenido principal

COMBINACION DE STRATEGIAS COMPUTACIONALES, BIOLOGICAS Y SINTETICAS CON APLICACION AL DESARROLLO DE FARMACOS

RTI2018-096100-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

AI in drug development: a multidisciplinary perspective

  • Gallego, Víctor
  • Naveiro Flores, Roi
  • Roca, Carlos
  • Ríos Insua, David
  • Campillo, Nuria E.
19 p.-5 fig.-1 graph. abst., The introduction of a new drug to the commercial market follows a complex and long process that typically spans over several years and entails large monetary costs due to a high attrition rate. Because of this, there is an urgent need to improve this process using innovative technologies such as artificial intelligence (AI). Different AI tools are being applied to support all four steps of the drug development process (basic research for drug discovery; pre-clinical phase; clinical phase; and postmarketing). Some of the main tasks where AI has proven useful include identifying molecular targets, searching for hit and lead compounds, synthesising drug-like compounds and predicting ADME-Tox. This review, on the one hand, brings in a mathematical vision of some of the key AI methods used in drug development closer to medicinal chemists and, on the other hand, brings the drug development process and the use of different models closer to mathematicians. Emphasis is placed on two aspects not mentioned in similar surveys, namely, Bayesian approaches and their applications to molecular modelling and the eventual final use of the methods to actually support decisions., This work was supported by and supported through the Spanish Ministry of Science and Innovation (RTI2018-096100-B-I00); MTM2017-86875-C3-1-R AEI/FEDER,UE; AXA -ICMAT Chair on Adversarial Risk Analysis; Adversarial Machine Learning: Methods, Computations and Applications to Malware, Fake News and Autonomous Vehicles– Ayudas Fundación BBVA a Equipos de Investigación Científca 2019. AItenea Biotech wants to thank Madrid Emprende for the Madrid Impacta 2020 award., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tideglusib, a non-ATP competitive inhibitor of GSK-3β as a drug candidate for the treatment of amyotrophic lateral sclerosis

  • Martínez-González, Loreto
  • Gonzalo-Consuegra, Claudia
  • Gómez-Almería, Marta
  • Porras, Gracia
  • De Lago, E.
  • Martín-Requero, Ángeles
  • Martínez Gil, Ana
14 p.-6 fig.-2 tab., Amyotrophic Lateral Sclerosis (ALS) is the most common degenerative motor neuron disease in adults. About 97% of ALS patients present TDP-43 aggregates with post-translational modifications, such as hyperphosphorylation, in the cytoplasm of affected cells. GSK-3β is one of the protein kinases involved in TDP-43 phosphorylation. Up-regulation of its expression and activity is reported on spinal cord and cortex tissues of ALS patients. Here, we propose the repurposing of Tideglusib, an in-house non-ATP competitive GSK-3β inhibitor that is currently in clinical trials for autism and myotonic dystrophy, as a promising therapeutic strategy for ALS. With this aim we have evaluated the efficacy of Tideglusib in different experimental ALS models both in vitro and in vivo. Moreover, we observed that GSK-3β activity is increased in lymphoblasts from sporadic ALS patients, with a simultaneous increase in TDP-43 phosphorylation and cytosolic TDP-43 accumulation. Treatment with Tideglusib decreased not only phospho-TDP-43 levels but also recovered its nuclear localization in ALS lymphoblasts and in a human TDP-43 neuroblastoma model. Additionally, we found that chronic oral treatment with Tideglusib is able to reduce the increased TDP-43 phosphorylation in the spinal cord of Prp-hTDP-43A315T mouse model. Therefore, we consider Tideglusib as a promising drug candidate for ALS, being proposed to start a clinical trial phase II by the end of the year., This research was funded by Madrid Community (B2017/BMD3813 ELA-Madrid), ISCiii (CIBERNED CB18/05/00040 and CB06/05/0089) and AEI (grant RTI2018-096100-B-I00 to Á.M.-R., PID2019-105600RB-I00 to A.M. and RTI2018-0988885-B-I00 to E.d.L.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multitarget drugs as potential therapeutic agents for alzheimer’s disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors

  • González-Naranjo, Pedro
  • Pérez, Concepción
  • González-Sánchez, Marina
  • Gironda-Martínez, Adrián
  • Ulzurrun, Eugenia
  • Bartolomé, Fernando
  • Rubio-Fernández, Marcos
  • Martín-Requero, Ángeles
  • Campillo, Nuria E.
  • Páez, Juan A.
Multitarget drugs are a promising therapeutic approach against Alzheimer’s disease. In this work, a new family of 5-substituted indazole derivatives with a multitarget profile including cholinesterase and BACE1 inhibition is described. Thus, the synthesis and evaluation of a new class of 5-substituted indazoles has been performed. Pharmacological evaluation includes in vitro inhibitory assays on AChE/BuChE and BACE1 enzymes. Also, the corresponding competition studies on BuChE were carried out. Additionally, antioxi- dant properties have been calculated from ORAC assays. Furthermore, studies of anti-inflammatory proper- ties on Raw 264.7 cells and neuroprotective effects in human neuroblastoma SH-SY5Y cells have been performed. The results of pharmacological tests have shown that some of these 5-substituted indazole derivatives 1–4 and 6 behave as AChE/BuChE and BACE1 inhibitors, simultaneously. In addition, some indazole derivatives showed anti-inflammatory (3, 6) and neuroprotective (1–4 and 6) effects against Ab- induced cell death in human neuroblastoma SH-SY5Y cells with antioxidant properties., This work was supported from Ministerio de Economía, Industria y Competitividad, Gobierno de Espa~na under Grant RTI2018-096100B-100., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TDP-43 pathology and prionic behavior in human cellular models of Alzheimer’s disease patients

  • Cuevas, Eva P.
  • Rodríguez-Fernández, Alberto
  • Palomo, Valle
  • Martínez Gil, Ana
  • Martín-Requero, Ángeles
19 p.-7 fig.-2 tab., Alzheimer’s disease (AD) is a neurodegenerative disorder for which there is currently no effective treatment. Despite advances in the molecular pathology of the characteristic histopathological markers of the disease (tau protein and β-amyloid), their translation to the clinic has not provided the expected results. Increasing evidences have demonstrated the presence of aggregates of TDP-43 (TAR DNA binding protein 43) in the postmortem brains of patients diagnosed with AD. The present research is focused on of the study of the pathological role of TDP-43 in AD. For this purpose, immortalized lymphocytes samples from patients diagnosed with different severity of sporadic AD were used and the TDP-43 pathology was analyzed against controls, looking for differences in their fragmentation, phosphorylation and cellular location using Western blot and immunocytochemical techniques. The results revealed an increase in TDP-43 fragmentation, as well as increased phosphorylation and aberrant localization of TDP-43 in the cytosolic compartment of lymphocytes of patients diagnosed with severe AD. Moreover, a fragment of approximately 25 KD was found in the extracellular medium of cells derived from severe AD individuals that seem to have prion-like characteristics. We conclude that TDP-43 plays a key role in AD pathogenesis and its cell to cell propagation., This work has been funded by AEI (grants PID2019-105600RB-I00 to AM, and grant RTI2018-096100-B-I00 to A.M-R); CM (grant B2017/BMD-3813) and ISCiii (grant CB18/05/00040, CIBERNED) and La Caixa grant LCF/BQ/PR18/11640007 to VP., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Design of new dispersants using machine learning and visual analytics

  • Martínez, María Jimena
  • Naveiro Flores, Roi
  • Soto, Axel J.
  • Talavante, Pablo
  • Kim Lee, Shin-Ho
  • Gómez Arrayas, Ramón
  • Franco, Mario
  • Mauleón, Pablo
  • Lozano Ordóñez, Héctor
  • Revilla López, Guillermo
  • Bernabei, Marco
  • Campillo, Nuria E.
  • Ponzoni, Ignacio
Artificial intelligence (AI) is an emerging technology that is revolutionizing the discovery of new materials. One key application of AI is virtual screening of chemical libraries, which enables the accelerated discovery of materials with desired properties. In this study, we developed computational models to predict the dispersancy efficiency of oil and lubricant additives, a critical property in their design that can be estimated through a quantity named blotter spot. We propose a comprehensive approach that combines machine learning techniques with visual analytics strategies in an interactive tool that supports domain experts’ decision-making. We evaluated the proposed models quantitatively and illustrated their benefits through a case study. Specifically, we analyzed a series of virtual polyisobutylene succinimide (PIBSI) molecules derived from a known reference substrate. Our best-performing probabilistic model was Bayesian Additive Regression Trees (BART), which achieved a mean absolute error of 5.50±0.34 and a root mean square error of 7.56±0.47, as estimated through 5-fold cross-validation. To facilitate future research, we have made the dataset, including the potential dispersants used for modeling, publicly available. Our approach can help accelerate the discovery of new oil and lubricant additives, and our interactive tool can aid domain experts in making informed decisions based on blotter spot and other key properties., This work was partially supported by DC Technology & Corporate Venturing of Repsol, by the Argentinean National Council of Scientific and Technological Research (CONICET for its acronym in Spanish) (Grants PIP 11220210100600CO, PIBAA 28720210101236CO, and PIBAA 2872021010048CO), by the National Agency for the Promotion of Research, Technological Development and Innovation of Argentina (AGENCIA I+D+i in Spanish), through the Fund for Scientific and Technological Research (FONCyT for its acronym in Spanish) (Grants PICT-2019-03350 and PICT-PRH-2021-00008), by the Universidad Nacional del Sur (UNS), Bahía Blanca, Argentina (Grant PGI 24/N042), and Ministerio de Economía, Industria y Competitividad, Gobierno de España under Grant RTI2018-096100B-100., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functional characterization of a familial ALS-associated missense TBK1 (p-Arg573Gly) mutation in patient-derived lymphoblasts

  • Porras, Gracia
  • Ruiz, Silvana
  • Maestro, Inés
  • Borrego-Hernández, Daniel
  • García-Redondo, Alberto
  • Martínez Gil, Ana
  • Martín-Requero, Ángeles
15 p.-6 fig.-1 tab., The goal of this work was to elucidate the pathogenic mechanism of an ALS-associated missense mutation, p.Arg573Gly (R573G), in the TBK1 gene. In particular, we seek to analyze the influence of this variant on the cellular levels and the function of TBK1 in immortalized cells from an ALS patient. The patient (Code# E7) belonged to a Spanish family with autosomal dominant disease manifesting in the sixth decade as either dementia or ALS. Four control individuals without signs of neurological disease were also included in this study. Our results indicate that the R375G TBK1 mutation did not affect the levels of mRNA nor the total TBK1 content; however, we observed a significant decrease in the levels of TBK1 phosphorylation, which is essential for TBK1 activity, as well as a significant reduction in the phosphorylation of p62 and RIPK1, known substrates for TBK1. Lymphoblasts from the R573G TBK1 mutation carrier patient display pathological TDP-43 homeostasis, showing elevated levels of phosphorylated TDP-43 and accumulation of the protein in the cytosolic compartment. In addition, the functional decrease in TBK1 activity observed in the E7 patient did not alter the autophagy flux, but it seems to be enough to increase ROS levels as well as the expression of pro-inflammatory cytokine IL-6., This work has been supported by grants from the ISCiii (CIBERNED, grant no. CB18/05/00040), AEI (grant no. RTI2018-096100-B-I00 and PID2019-105600RB-I00), Comunidad de Madrid (grant no. B2017/BMD-3813), and Fundación La Caixa-Fundación Luzón (grant no. HR21-00931)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Progranulin deficiency induces mitochondrial dysfunction in frontotemporal lobar degeneration with TDP-43 inclusions

  • Rodriguez-Perinan, Guiomar
  • De la Encarnación, Ana
  • Moreno, Fermín
  • López de Munain, Adolfo
  • Martínez Gil, Ana
  • Martín-Requero, Ángeles
  • Alquézar, Carolina
  • Bartolomé Robledo, Fernando
20 p.-6 fig.-1 tab., Loss-of-function (LOF) mutations in GRN gene, which encodes progranulin (PGRN), cause frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). FTLD-TDP is one of the most common forms of early onset dementia, but its pathogenesis is not fully understood. Mitochondrial dysfunction has been associated with several neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). Here, we have investigated whether mitochondrial alterations could also contribute to the pathogenesis of PGRN deficiency-associated FTLD-TDP. Our results showed that PGRN deficiency induced mitochondrial depolarization, increased ROS production and lowered ATP levels in GRN KD SH-SY5Y neuroblastoma cells. Interestingly, lymphoblasts from FTLD-TDP patients carrying a LOF mutation in the GRN gene (c.709-1G > A) also demonstrated mitochondrial depolarization and lower ATP levels. Such mitochondrial damage increased mitochondrial fission to remove dysfunctional mitochondria by mitophagy. Interestingly, PGRN-deficient cells showed elevated mitochondrial mass together with autophagy dysfunction, implying that PGRN deficiency induced the accumulation of damaged mitochondria by blocking its degradation in the lysosomes. Importantly, the treatment with two brain-penetrant CK-1δ inhibitors (IGS-2.7 and IGS-3.27), known for preventing the phosphorylation and cytosolic accumulation of TDP-43, rescued mitochondrial function in PGRN-deficient cells. Taken together, these results suggest that mitochondrial function is impaired in FTLD-TDP associated with LOF GRN mutations and that the TDP-43 pathology linked to PGRN deficiency might be a key mechanism contributing to such mitochondrial dysfunction. Furthermore, our results point to the use of drugs targeting TDP-43 pathology as a promising therapeutic strategy for restoring mitochondrial function in FTLD-TDP and other TDP-43-related diseases., This study was supported by funding from the “Instituto de Salud Carlos III” (grant numbers CP21/00049, CP20/00007, PI21/00183 and PI22/00345), Fundación Eugenio Rodriguez Pascual (FERP-2022-5) CIBERNED (grant number CB18/05/00040), “Agencia Estatal de Investigación” (grant number RTI2018-096100-B-I00 and PID2019-105600RB-I00), “Comunidad de Madrid” (grant number B2017/BMD-3813) and Fundación La Caixa-Fundación Luzón (grant HR21-00931)., Peer reviewed